Arrowstreet Capital’s Fate Therapeutics FATE Stock Holding History

Arrowstreet Capital’s Portfolio FATE Stock Details FATE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$5.63M	Buy	2,374,346 +2,344,170	+7,768%	+$6.06M	﹤0.01%	1218
2026 Q2	$81.5K	Buy	+30,176	New	+$55.8K	﹤0.01%	1877
2025 Q1	–	Sell	-25,580	Closed	-$42.2K	–	1867
2024 Q4	$42.2K	Sell	25,580 -6,518	-20%	-$16.4K	﹤0.01%	1700
2024 Q3	$112K	Buy	+32,098	New	+$125K	﹤0.01%	1679
2021 Q4	–	Sell	-25,100	Closed	-$1.49M	–	1522
2021 Q3	$1.49M	Buy	25,100 +21,300	+561%	+$1.67M	﹤0.01%	1203
2021 Q2	$330K	Buy	+3,800	New	+$306K	﹤0.01%	1732
2021 Q1	–	Sell	-69,636	Closed	-$6.33M	–	2323
2020 Q4	$6.33M	Buy	69,636 +35,477	+104%	+$2.2M	0.01%	1101
2020 Q3	$1.36M	Buy	+34,159	New	+$1.19M	﹤0.01%	1710
2020 Q1	–	Sell	-31,900	Closed	-$624K	–	1942
2019 Q4	$624K	Buy	+31,900	New	+$507K	﹤0.01%	1447
2019 Q2	–	Sell	-19,300	Closed	-$339K	–	1480
2019 Q1	$339K	Buy	19,300 +8,530	+79%	+$135K	﹤0.01%	1564
2018 Q4	$138K	Buy	+10,770	New	+$150K	﹤0.01%	1283

Other funds holding FATE

BlackRock New York $6.79T AUM 37.06% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.21T AUM

Acadian Asset Management Boston, Massachusetts $85.7B AUM 51.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.76T AUM

Johnson & Johnson New Brunswick, New Jersey $762M AUM 69.66% 1-Year Est. Return

Renaissance Technologies New York $73.4B AUM 32.8% 1-Year Est. Return

Qube Research & Technologies (QRT) London, United Kingdom $123B AUM 30.05% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $103B AUM 40.17% 1-Year Est. Return

Connor, Clark & Lunn Investment Management (CC&L) Vancouver, British Columbia, Canada $57.2B AUM 42.49% 1-Year Est. Return

Arrowstreet Capital's FATE Position: Q3 2026 in Review

Arrowstreet Capital increased its Fate Therapeutics (FATE) stake by 7,768% in Q3 2026, buying an estimated $6.06M and bringing the position to 2,374,346 shares worth $5.63M. The position accounts for ﹤0.01% of the portfolio, ranked #1218.

Arrowstreet Capital first reported a position in FATE in Q4 2018 and has held it in 11 quarters since. The position peaked at $6.33M in Q4 2020. 101 funds tracked by Wall St. Rank hold FATE as of Q3 2026.

Arrowstreet Capital held 2,374,346 shares of Fate Therapeutics worth $5.63M as of Q3 2026.
Arrowstreet Capital bought 2,344,170 Fate Therapeutics shares in Q3 2026, an estimated $6.06M.
Fate Therapeutics made up ﹤0.01% of Arrowstreet Capital's portfolio in Q3 2026, its #1218 holding.
Arrowstreet Capital first reported a position in Fate Therapeutics in Q4 2018 and has held it in 11 quarters since.
Arrowstreet Capital's Fate Therapeutics position peaked at $6.33M in Q4 2020.
101 funds tracked by Wall St. Rank held Fate Therapeutics as of Q3 2026.

Based on Arrowstreet Capital's 13F filing for Q3 2026, filed 13 Nov 2026.